electroCore Announces First Quarter 2021 Financial Results
May 06, 2021 16:12 ET
|
electroCore, Inc.
Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially Company to host a conference call and webcast today, May 6, 2021 at 4:30 pm ET ...
electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache
May 04, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, May 04, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the U.S. Department of Veterans Affairs is...
electroCore to Announce First Quarter 2021 Financial Results on Thursday, May 6
April 29, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, April 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first...
electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders
April 26, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, April 26, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of...
electroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar
April 20, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, April 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with East...
electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache
April 15, 2021 07:59 ET
|
electroCore, Inc.
ROCKAWAY, NJ, April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled,...
electroCore Provides Business Update and Select First Quarter 2021 Financial Guidance
April 13, 2021 07:59 ET
|
electroCore, Inc.
First-quarter 2021 revenue expected to be more than $1.1 millionNet cash used for the first quarter 2021 of approximately $4.1 million ROCKAWAY, NJ, April 13, 2021 (GLOBE NEWSWIRE) --...
electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
April 08, 2021 07:59 ET
|
electroCore, Inc.
ROCKAWAY, NJ, April 08, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the top-line results from the SAVIOR-1 study, a...
electroCore, Inc. Announces Regulatory Approval in Canada
April 05, 2021 07:59 ET
|
electroCore, Inc.
ROCKAWAY, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory...